title: [A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1].
abstract: We report a 60-year-old female with pulmonary metastasis from breast cancer who responded to S-1. In November 2001, she underwent surgery. In October 2005, relapse was detected. As there was no hormone sensitivity, chemotherapy was selected, and oral administration of S-1 at 120 mg/day (2 divided doses) was initiated. After the fourth course, the tumor marker level returned to the reference value. Thoracic CT at the end of the sixth course revealed the disappearance of the metastatic focus. Adverse reactions during the administration period were mild. S-1 showed potent antitumor effects and good tolerance, and it may be useful for treating metastatic/recurrent breast cancer.
authors.affiliation: Dept. of Surgery, Saiseikai Central Hospital.
authors.forename: Kimiyasu
authors.initials: K
authors.lastname: Yoneyama
authors.forename: Aki
authors.initials: A
authors.lastname: Yamada
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Koshida
authors.forename: Fumiki
authors.initials: F
authors.lastname: Toriumi
authors.forename: Takaya
authors.initials: T
authors.lastname: Murayama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Toeda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Imazu
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Motegi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Akamatsu
authors.forename: Renpei
authors.initials: R
authors.lastname: Ooyama
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000601:surgery*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery*; D002272:Carcinoembryonic Antigen / Q000097:blood; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D015412:Mastectomy, Segmental; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D010094:Oxonic Acid / Q000627:therapeutic use*; D011788:Quality of Life; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D004338:Drug Combinations; D018396:Mucin-1; C056315:ST 439 antigen, human; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid